Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
Checkpoint inhibitors
Metastatic melanoma
Neutrophil-to-lymphocyte ratio
Platelet-to-lymphocyte ratio
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
05 04 2022
05 04 2022
Historique:
received:
03
01
2022
accepted:
24
03
2022
entrez:
6
4
2022
pubmed:
7
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
To evaluate the capability of basal and one-month differed white blood cells (WBC), neutrophil, lymphocyte and platelet values and their ratios (neutrophils-to-lymphocytes ratio, NLR, and platelets-to-lymphocytes ratio, PLR) in predicting the response to immune checkpoint inhibitors (ICI) in metastatic melanoma (MM). We performed a retrospective study of 272 BRAF wild-type MM patients treated with first line ICI. Bivariable analysis was used to correlate patient/tumor characteristics with clinical outcomes. Variations between time 1 and time 0 (Δ) of blood parameters were also calculated and dichotomized using cut-off values assessed by ROC curve. At baseline, higher neutrophils and NLR negatively correlated with PFS, OS and disease control rate (DCR). Higher PLR was also associated with worse OS. In multivariable analysis, neutrophils (p = 0.003), WBC (p = 0.069) and LDH (p = 0.07) maintained their impact on PFS, while OS was affected by LDH (p < 0.001), neutrophils (p < 0.001) and PLR (p = 0.022), while DCR by LDH (p = 0.03) and neutrophils (p = 0.004). In the longitudinal analysis, PFS negatively correlated with higher Δplatelets (p = 0.039), ΔWBC (p < 0.001), and Δneutrophils (p = 0.020), and with lower Δlymphocytes (p < 0.001). Moreover, higher ΔNLR and ΔPLR identified patients with worse PFS, OS and DCR. In the multivariable model, only ΔNLR influenced PFS (p = 0.004), while OS resulted affected by higher ΔWBC (p < 0.001) and lower Δlymphocytes (p = 0.038). Higher ΔWBC also affected the DCR (p = 0.003). When clustering patients in 4 categories using basal LDH and ΔNLR, normal LDH/lower ΔNLR showed a higher PFS than high LDH/higher ΔNLR (20 vs 5 months). Moreover, normal LDH/higher Δlymphocytes had a higher OS than high LDH/lower Δlymphocytes (50 vs. 10 months). Baseline and early variations of blood cells, together with basal LDH, strongly predict the efficacy of ICI in MM. Our findings propose simple, inexpensive biomarkers for a better selection of patient treatments. Prospective multicenter studies are warranted to confirm these data.
Sections du résumé
BACKGROUND
To evaluate the capability of basal and one-month differed white blood cells (WBC), neutrophil, lymphocyte and platelet values and their ratios (neutrophils-to-lymphocytes ratio, NLR, and platelets-to-lymphocytes ratio, PLR) in predicting the response to immune checkpoint inhibitors (ICI) in metastatic melanoma (MM).
METHODS
We performed a retrospective study of 272 BRAF wild-type MM patients treated with first line ICI. Bivariable analysis was used to correlate patient/tumor characteristics with clinical outcomes. Variations between time 1 and time 0 (Δ) of blood parameters were also calculated and dichotomized using cut-off values assessed by ROC curve.
RESULTS
At baseline, higher neutrophils and NLR negatively correlated with PFS, OS and disease control rate (DCR). Higher PLR was also associated with worse OS. In multivariable analysis, neutrophils (p = 0.003), WBC (p = 0.069) and LDH (p = 0.07) maintained their impact on PFS, while OS was affected by LDH (p < 0.001), neutrophils (p < 0.001) and PLR (p = 0.022), while DCR by LDH (p = 0.03) and neutrophils (p = 0.004). In the longitudinal analysis, PFS negatively correlated with higher Δplatelets (p = 0.039), ΔWBC (p < 0.001), and Δneutrophils (p = 0.020), and with lower Δlymphocytes (p < 0.001). Moreover, higher ΔNLR and ΔPLR identified patients with worse PFS, OS and DCR. In the multivariable model, only ΔNLR influenced PFS (p = 0.004), while OS resulted affected by higher ΔWBC (p < 0.001) and lower Δlymphocytes (p = 0.038). Higher ΔWBC also affected the DCR (p = 0.003). When clustering patients in 4 categories using basal LDH and ΔNLR, normal LDH/lower ΔNLR showed a higher PFS than high LDH/higher ΔNLR (20 vs 5 months). Moreover, normal LDH/higher Δlymphocytes had a higher OS than high LDH/lower Δlymphocytes (50 vs. 10 months).
CONCLUSIONS
Baseline and early variations of blood cells, together with basal LDH, strongly predict the efficacy of ICI in MM. Our findings propose simple, inexpensive biomarkers for a better selection of patient treatments. Prospective multicenter studies are warranted to confirm these data.
Identifiants
pubmed: 35382857
doi: 10.1186/s12967-022-03359-x
pii: 10.1186/s12967-022-03359-x
pmc: PMC8981693
doi:
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
159Informations de copyright
© 2022. The Author(s).
Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33593828
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Ann Palliat Med. 2020 Sep;9(5):3271-3277
pubmed: 32921118
Sci Rep. 2019 Dec 23;9(1):19673
pubmed: 31873162
Ann Oncol. 2018 Feb 1;29(2):524
pubmed: 28379318
Drug Discov Ther. 2020 Jul 15;14(3):117-121
pubmed: 32595179
Br J Dermatol. 2016 Jan;174(1):146-51
pubmed: 26343230
Cancers (Basel). 2019 Oct 14;11(10):
pubmed: 31615127
Clin Chim Acta. 2018 Sep;484:136-140
pubmed: 29856976
J Am Acad Dermatol. 2018 Jul;79(1):165-167.e2
pubmed: 29544740
J Immunother Cancer. 2018 Jul 16;6(1):74
pubmed: 30012216
J Immunol. 1987 Oct 1;139(7):2406-13
pubmed: 2821114
Cancer Biomark. 2016 Jun 7;17(1):33-40
pubmed: 27314290
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
J Hematol Oncol. 2018 Oct 11;11(1):125
pubmed: 30305116
EBioMedicine. 2017 Apr;18:56-61
pubmed: 28356222
Cancer Immunol Immunother. 2013 Jun;62(6):1021-8
pubmed: 23591982
Cancer. 2019 Jan 1;125(1):127-134
pubmed: 30329148
Eur J Cancer. 2021 Jun;150:155-167
pubmed: 33901794
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
Cancer Med. 2019 Aug;8(9):4135-4148
pubmed: 31197958
Haemostasis. 1988;18(1):18-28
pubmed: 3047020
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Int Med Res. 2020 Dec;48(12):300060520980205
pubmed: 33350871
Cancer. 2020 Jan 1;126(1):76-85
pubmed: 31584709
Immunotherapy. 2020 Aug;12(11):785-798
pubmed: 32657234
Curr Pharm Des. 2011;17(1):47-58
pubmed: 21247392
Mol Cancer. 2017 Aug 15;16(1):137
pubmed: 28810877
Science. 2016 Apr 8;352(6282):145-6
pubmed: 27124439
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581042
J Oncol. 2012;2012:608406
pubmed: 22927846
Ann Oncol. 2016 Apr;27(4):732-8
pubmed: 26802161
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Sci Rep. 2016 Oct 14;6:35378
pubmed: 27739490
J Immunother Cancer. 2018 Jan 22;6(1):5
pubmed: 29353553
Pharmacol Ther. 2021 Jan;217:107662
pubmed: 32805297
Breast Cancer Res. 2017 Jan 5;19(1):2
pubmed: 28057046
Front Oncol. 2020 Jul 28;10:1116
pubmed: 32850320